Matthew Keller
Stock Analyst at HC Wainwright & Co.
(0.31)
# 4,212
Out of 5,241 analysts
13
Total ratings
16.67%
Success rate
-19.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IFRX InflaRx | Maintains: Buy | $6 → $8 | $2.37 | +237.55% | 3 | May 11, 2026 | |
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $1.06 | +1,220.75% | 2 | Feb 10, 2026 | |
| SXTP 60 Degrees Pharmaceuticals | Maintains: Buy | $6 → $24 | $1.41 | +1,602.13% | 2 | Jan 27, 2026 | |
| GALT Galectin Therapeutics | Maintains: Buy | $6 → $11 | $2.08 | +428.85% | 2 | Dec 17, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $16.77 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $1.88 | +1,548.94% | 2 | Sep 30, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $6.26 | +187.54% | 1 | Aug 26, 2025 |
InflaRx
May 11, 2026
Maintains: Buy
Price Target: $6 → $8
Current: $2.37
Upside: +237.55%
Phio Pharmaceuticals
Feb 10, 2026
Reiterates: Buy
Price Target: $14
Current: $1.06
Upside: +1,220.75%
60 Degrees Pharmaceuticals
Jan 27, 2026
Maintains: Buy
Price Target: $6 → $24
Current: $1.41
Upside: +1,602.13%
Galectin Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $6 → $11
Current: $2.08
Upside: +428.85%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $16.77
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $1.88
Upside: +1,548.94%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $6.26
Upside: +187.54%